Description
The National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate a contract with Emmes for clinical trial monitoring services. The goal of the clinical trial is to evaluate progression-free and overall survival in participants with recurrent glioblastoma receiving LMP744 compared to historic controls. The contractor will be responsible for data collection, data abstraction, data identification, data validation, communication among clinical team, and understanding of clinical research protocol. The period of performance will be for a base year with four option years, with a total estimated level of effort of 1634 hours over five years. The contractor will be required to have access to government CTDB database reports and collaborate with the clinical team.
• The clinical trial will involve 40 participants with recurrent glioblastoma.
• The contractor will be responsible for overseeing clinical research efforts away from direct patient care.
• The place of performance will be a combination of onsite at the National Institutes of Health campus in Bethesda, Maryland, and remote work.
• The contractor will be required to handle data/information with discretion prior to publication.